All Drug Targets articles – Page 22
-
VideoVideo: Dianthus for identifying Microcycle® hits
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
-
NewsPotential new therapies for primary open-angle glaucoma
Researchers have gained a better understanding of the genes and biological processes that could influence POAG pathogenesis.
-
NewsUncovering the bidirectional relationship between PD and DM
Single-cell RNA analysis provides an immunological explanation for the association between periodontitis and diabetes mellitus.
-
ArticleThe role of anti-viral drug development in a new pandemic era
As humanity faces an impending era of pandemics, global collaboration among governments, organisations and industry is critical. In this article, epidemiologist Dr Jay Varma explores the urgent need for researching and developing drugs to combat a range of epidemic-prone pathogens, and reflects on the increased risk of spillovers and the ...
-
News
Novel target found for CDKL5 deficiency disorder
Scientists have discovered that increasing the levels of the CDKL2 enzyme could stop CDD symptoms developing or worsening.
-
NewsNew therapeutic targets for stress related disorders
A mechanism by which the immune system influences central nervous system function and behaviour has been discovered.
-
ArticleeBook: Reveal Cell Function With Single-Cell Resolution
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
-
ArticleInvestigating the intratumoural microbiome in young-onset CRC patients
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
-
NewsImproving treatments for rheumatoid arthritis patients
Researchers found that resolvinT4 restores protective macrophage biological activities in rheumatoid arthritis patients.
-
WhitepaperMEA to probe ALS phenotypes in neuronal disease models
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
-
NewsAdvancing the understanding of placenta accreta spectrum disorder
A new study has identified targets to refine diagnostic tests, track disease progression, and discover more effective therapies.
-
WhitepaperApplication Note: Understanding The Multiplex Imaging Landscape
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
-
WhitepaperApplication note: In situ identification of cancer stem cell niches (HCC)
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).
-
NewsReplacing the PKP2 gene prolongs survival in ARVC patients
The new study suggests that this gene therapy method may combat ARVC in both early and more advanced stages of the condition.
-
WhitepaperConsistent, functional lower motor neurons from iPSCs
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
-
NewsKnockdown of FAM3C inhibits breast cancer tumour growth
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
-
News
Blocking the IL-6 receptor to protect tissues from CRS
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
-
NewsFinding the fundamental pathway in ALD pathogenesis
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
-
NewsHow breast cancer cells take advantage of the extracellular matrix
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
-
NewsRBM5: potential drug target for acute myeloid leukaemia
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.